Search results for "chemoradiotherapy"

showing 10 items of 120 documents

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Smal…

2015

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 ev…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentMedizinPhases of clinical researchVinblastineVinorelbineDrug Administration SchedulePneumonectomyCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPneumonectomyLung cancerAgedNeoplasm Stagingbusiness.industryDose fractionationInduction chemotherapyVinorelbineChemoradiotherapyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyFemaleDose Fractionation RadiationCisplatinbusinessChemoradiotherapymedicine.drugJournal of Clinical Oncology
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

2010

Purpose To assess response of locally advanced rectal carcinoma to chemoradiation with regard to mucinous status and local tumor invasion found at pretherapeutic magnetic resonance imaging (MRI). Methods and Materials A total of 88 patients were included in this prospective study of patients with advanced mrT3 and mrT4 carcinomas. Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous. Patients received neoadjuvant chemoradiation consisting of 50.4 Gy (1.8 Gy/fraction) and 5-fluorouracil on Days 1 to 5 and Days 29 to 33. Therapy response was assessed by comparing pretherapeutic MRI with histopathology of surgical specimens (minimum…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAntimetabolites AntineoplasticNeoplasm ResidualColorectal cancerRectumDrug Administration SchedulemedicineMucinous carcinomaHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overRadiationmedicine.diagnostic_testbusiness.industryRectal NeoplasmsCarcinomaDose fractionationMagnetic resonance imagingChemoradiotherapyMiddle Agedmedicine.diseaseAdenocarcinoma MucinousMagnetic Resonance ImagingNeoadjuvant TherapyTumor Burdenmedicine.anatomical_structureTreatment OutcomeOncologyAdenocarcinomaHistopathologyFemaleRadiologyDose Fractionation RadiationFluorouracilbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial

2013

Background: RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We analysed RAS mutations in 30 non-metastatic rectal cancer patients treated with or without cetuximab within the 31 EXPERT-C trial. Methods: Ninety of 149 patients with tumours available for analysis were KRAS/BRAF wild-type, and randomly assigned to capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery and adjuvant CAPOX or the same regimen plus cetuximab (CAPOX-C). Of these, four had a mutation of NRAS exon 3, and 84 were retrospectively analysed for additional KRAS (exon 4) and NRAS (exons 2/4) mutations by using bi-di…

AdultMaleOncologyNeuroblastoma RAS viral oncogene homologCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerPopulationCetuximabAntibodies Monoclonal Humanizedmedicine.disease_causeDeoxycytidineCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationneoplasmsCapecitabineAgedRetrospective Studieseducation.field_of_studyCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapySequence Analysis DNAMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinOxaliplatinTreatment OutcomeOncologyMutationras ProteinsFemaleFluorouracilKRASbusinessChemoradiotherapymedicine.drugEuropean Journal of Cancer
researchProduct

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers

2013

The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear. Here, we report on a retrospective study of 47 patients with either newly diagnosed (30 patients) or recurrent (17 patients) glioblastoma (WHO grade IV) treated with BCNU (bis-chloroethylnitrosourea) wafers. Thirteen of the newly diagnosed patients received local BCNU and irradiation only (first-line BCNU), while 17 patients additionally received concomitant and adjuvant temozolomide (TMZ) radiochemotherapy (first-line BCNU + TMZ). Of the 17 patients treated for recurrent glioblastoma (second-line BCNU), 16 had rec…

AdultMaleOncologymedicine.medical_specialtyMethyltransferaseDacarbazineDisease-Free SurvivalO(6)-Methylguanine-DNA Methyltransferase03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsTemozolomidemedicineHumansKarnofsky Performance StatusPromoter Regions GeneticAntineoplastic Agents AlkylatingSurvival analysisAgedRetrospective StudiesCarmustineTemozolomideBrain Neoplasmsbusiness.industryO-6-methylguanine-DNA methyltransferaseChemoradiotherapyGeneral MedicineDNA MethylationMiddle AgedPrognosisCarmustineCombined Modality TherapySurvival Analysis3. Good healthSurgeryDacarbazine030220 oncology & carcinogenesisConcomitantFemaleSurgeryNeurology (clinical)Glioblastomabusiness030217 neurology & neurosurgeryChemoradiotherapymedicine.drugBritish Journal of Neurosurgery
researchProduct

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diag…

2019

Adult neuroblastoma is an extremely infrequent neoplasm, usually occurring in the adrenal medulla or in the paraspinal sympathetic ganglia, as its childhood counterpart. We report a very unusual case of a Schwannian stroma-poor adult neuroblastoma of inguinal location, showing aberrant expression of germ cell markers: SALL4 and OCT4. This aberrant marker expression, the unusual positivity for NKX2.2 and the very scattered (instead of diffuse strong) PHOX2B expression, complicated the initial diagnosis. In this case, the posttreatment histological evaluation revealed the neuroblastic nature of the lesion. Neuroblastoma maturation after treatment is an unusual finding in adults, and in this …

AdultMalePathologymedicine.medical_specialtymedicine.medical_treatmentInguinal CanalBiologyPathology and Forensic MedicineDiagnosis DifferentialLesionNeuroblastomaSALL4NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansIfosfamideCyclophosphamideEtoposideHomeodomain ProteinsChemotherapyExtra-AdrenalNuclear ProteinsChemoradiotherapymedicine.diseaseGerm CellsHomeobox Protein Nkx-2.2medicine.anatomical_structureVincristineAbdominal NeoplasmsDactinomycinSurgeryAnatomymedicine.symptomAdrenal medullaOctamer Transcription Factor-3Germ cellAfter treatmentTranscription FactorsInternational Journal of Surgical Pathology
researchProduct

Local excision for more advanced rectal tumors

2008

Over the past 20 years, local excision (LE) of T1 rectal cancer was increasingly established and represents an oncologically established technique. In contrast, the situation for T2 tumors is less clear and has only been investigated in small patient collectives. LE for T2 tumors is thus discussed controversially.In addition to our own patients with T2 rectal cancer treated locally (n=40), we have analysed the local recurrence (LR) rates after LE alone (n=124), after immediate conventional radical reoperation (n=29), after adjuvant (chemo)-radiotherapy (n=294) and those after neoadjuvant chemoradiotherapy (nCRT) (n=269) using a PubMed search.LR rates of low-grade T2 tumors after R0 resectio…

AdultMaleReoperationLocal excisionmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentRectal TumorsmedicineAdjuvant therapyHumansRadiology Nuclear Medicine and imagingDigestive System Surgical ProceduresAgedNeoplasm StagingR0 resectionRectal Neoplasmsbusiness.industryCarcinomaHematologyGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapySurgeryOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessAdjuvantFollow-Up StudiesNeoadjuvant chemoradiotherapyActa Oncologica
researchProduct

Prophylactic chimera anterolateral thigh/vastus lateralis flap: preventing complications in high-risk head and neck reconstruction

2014

Purpose In high-risk head and neck cases treated with tumor resection and associated radical neck dissection, orocutaneous fistulas and wound breakdowns in the neck are relatively frequent and can have serious consequences, such as carotid blowout syndrome (CBS), the need for salvage reoperations, and prolonged recovery time. The authors present the application of a prophylactic chimeric anterolateral thigh (ALT) and vastus lateralis (VL) flap to prevent complications. Materials and Methods A retrospective review was performed of a historical group (96 patients) of patients with head and neck cancer treated with tumor resection, radical neck dissection, and microsurgical reconstruction of t…

AdultMaleReoperationMicrosurgerymedicine.medical_specialtyCutaneous FistulaFistulamedicine.medical_treatmentBlood Loss SurgicalSettore MED/19 - Chirurgia PlasticaSurgical FlapsCohort StudiesPostoperative ComplicationsNeck MusclesSurgical Wound DehiscencemedicineHumansProspective StudiesIntraoperative ComplicationsMuscle SkeletalProspective cohort studyAgedRetrospective StudiesSalvage Therapybusiness.industryHead and neck cancerSoft tissueNeck dissectionChemoradiotherapy AdjuvantMiddle AgedPlastic Surgery Proceduresmedicine.diseaseNeoadjuvant TherapySurgeryLaryngectomyChimera Anterolateral Thigh/Vastus Lateralis Flap Head and neck reconstructionOtorhinolaryngologyHead and Neck NeoplasmsCohortNeck DissectionFemaleSurgeryOral SurgeryCarotid Artery InjuriesSternocleidomastoid musclebusinessOral FistulaFollow-Up Studies
researchProduct

Is There an Indication for Intraoperative MRI in Subtotal Resection of Glioblastoma? A Multicenter Retrospective Comparative Analysis.

2017

Objective Surgery in patients with highly eloquent glioblastoma (GB) remains challenging. The aim of this study was to evaluate influence of use of intraoperative magnetic resonance imaging (iMRI) on extent of resection (EOR), clinical outcome, and survival in patients with preoperatively intended subtotal resection of GB. Methods Retrospective assessment was performed in 3 neurosurgical centers (2008–2013). All patients with primary GB, unilocular growth, and adjuvant radiochemotherapy in whom subtotal resection was intended were included. Imaging data were pseudonymized and volumetrically assessed by a central reviewer. Clinical outcome was evaluated based on complications, new permanent …

AdultMalemedicine.medical_specialtyAdolescentInterventional magnetic resonance imagingMagnetic Resonance Imaging InterventionalNeurosurgical ProceduresIntraoperative MRI03 medical and health sciencesYoung Adult0302 clinical medicinePostoperative ComplicationsmedicineHumansAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryProportional hazards modelBrain NeoplasmsMagnetic resonance imagingSubtotal ResectionOdds ratioChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseSurgeryTreatment Outcome030220 oncology & carcinogenesisMultivariate AnalysisLinear ModelsSurgeryFemaleNeurology (clinical)PseudonymizedbusinessGlioblastoma030217 neurology & neurosurgeryGlioblastomaWorld neurosurgery
researchProduct